Amgen (AMGN) concluded the recent trading session at $311.55, signifying a +1.5% move from its prior day's close.

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In its Thousand Oaks hometown in California, it was far and away the biggest employer, with 1 in 10 of the town folk working for Amgen. It built sites throughout Europe and Asia, and became even ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by ...

Shares of Amgen Inc. AMGN shed 2.39% to $306.86 Tuesday, on what proved to be an all-around favorable trading session for the ...

Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual ...

The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly launched trials. Historically, the California-based pharma has remained ...